TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00732069
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
Study: NCT01835938
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Placebo 50 mg tablet by mouth every day for 14 days,~* Placebo 100 mg tablet by mouth every day for 14 days,~* Placebo 150 mg tablet by mouth every day for 14 days,
Study: NCT02140281
Drug: Treatment A (cefadroxil alone)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 500 mg oral dose of cefadroxil will be given on the morning of Day 1
Study: NCT02037633
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl IV
Study: NCT01825928
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo group,3mg/pill,3mg/day forced titration method,last 84 days
Study: NCT02055781
Drug: Best Available Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00194987
Drug: IVIG (Intravenous Immunoglobulin)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: one gram per kg of IVIG per infusion given either once or twice
Study: NCT00542243
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given once a day for 6 months.
Study: NCT03363971
Drug: Simulant agent for Zhi Kang Capsule
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3g/capsule,oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery; treatment for 6 weeks.
Study: NCT01824082
Drug: Perineural infusion [continuous peripheral nerve block(s)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic, programmable, portable infusion pumps will be used to administer perineural study solution at fixed rates for over 6 days. Subjects will receive a total of 1,100 mL of study fluid from either one (upper extremity) or two (lower extremity) pump and external reservoir combinations. The continuous basal infusion rate will be determined by catheter location: femoral 2.5 mL/h; popliteal-sciatic 5 mL/h; and infraclavicular 7.5 mL/h (37.5 mg/h for both upper and lower extremity subjects). No patient-controlled bolus dose will be included. Subjects will have the option of returning 4-16 weeks later for a second infusion of the alternate treatment solution.
Study: NCT01616290
Drug: PRT-201
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03, 1, or 3 mg single adventitial administration
Study: NCT01822028
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Florastor® placebo. Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day).
Study: NCT01822028
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Florastor® capsules dosed at 1000 mg daily (two 250 mg capsules two times per day).~Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day).
Study: NCT00315445
Drug: Placebo oxycodone/acetaminophen tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oxycodone/acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
Study: NCT00315445
Drug: OXY/APAP
Normalized name: Acetaminophen/Propoxyphene Hydrochloride 650 MG-65 MG Oral Tablet [PROPOXY/APAP-65]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oxycodone / 325 mg acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
Study: NCT00315445
Drug: Placebo transdermal patch (TDS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo transdermal patch 5, 10, or 20 applied transdermally for 7-day wear
Study: NCT00684983
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03712098
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is an inactive substance that is designed to look like liraglutide but contains no medication.
Study: NCT00434005
Drug: N-acetylcysteine, ascorbate
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAC: 600mg twice daily for the day prior to exposure and 1x pre-exposure Ascorbate: 500mg twice daily for 7 days prior to exposure
Study: NCT00434005
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched appearance to acetylcysteine and ascorbate intervention
Study: NCT00959803
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution, oral single dose.
Study: NCT00949442
Drug: human insulin [NPH]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 IU/ml suspension for injection in a prefilled pen OptiSet® (3 ml)
Study: NCT00959803
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution, oral twice daily for 7 days.
Study: NCT04410523
Drug: CSJ117
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSJ117 inhaled once daily (in the morning) for 12 weeks. Delivered via Concept1 device.~CSJ117 = inhaled monoclonal antibody fragment
Study: NCT04410523
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Run-in period (all arms): Placebo inhaled once daily (in the morning) for 4 weeks. Placebo dosing extended to 8 weeks in case of asthma exacerbation or respiratory tract infection during this period.~Treatment period (Placebo arm only): Placebo inhaled once daily (in the morning) for 12 weeks. Delivered via Concept1 device.
Study: NCT03787927
Drug: Autologous Platelet Transfusion (room-temperature-stored)
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participant will receive an autologous platelet transfusion of their room-temperature-stored platelets after 5 days of storage.
Study: NCT03787927
Drug: Autologous Platelet Transfusion (cold-stored 5 days)
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participant will receive an autologous platelet transfusion of their cold-stored platelets after 5 days of storage.
Study: NCT03787927
Drug: Autologous Platelet Transfusion (cold-stored 10 days)
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participant will receive an autologous platelet transfusion of their cold-stored platelets after 10 days of storage.
Study: NCT00359216
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray. Each subject to take 4 sprays once daily in the morning.
Study: NCT01505283
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: epidural administration of 6 ml of NaCl 0.9%
Study: NCT01505283
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: epidural administration of sufentanil 10 µg
Study: NCT00261105
Drug: telithromycin
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01651364
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled volunteers will be randomized on Day 8 to receive placebo (n=2) or study medication (n=8). Placebo serves only to maintain the blind and is not a comparator.
Study: NCT03368664
Drug: Ceterizine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet, Route of administration: oral
Study: NCT00522873
Drug: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 13 cycles (28 days per cycle).
Study: NCT00522873
Drug: 0.5mg NETA / 1.0mg E2 (Activella)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule \[0.5mg norethisterone acetate/1.0mg 17β-estradiol (NETA/E2)\] per day taken orally for 13 cycles (28 days per cycle).
Study: NCT03368664
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet, Route of administration: oral
Study: NCT03368664
Drug: Diphenydramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution, Route of administration: IV
Study: NCT03381014
Drug: Chemotherapy, Cancer, Anthracyclines
Approvals — FDA: no, EMA: no, PMDA: no
Description: follow up cardio-toxicity .... by speckle tracking echo and cardiac troponin
Study: NCT00683449
Drug: Dose Group 1
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of MN-221 16 mcg/min for 15 min; total dose of 240 mcg
Study: NCT00683449
Drug: MN-221 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusion of placebo for 15 minutes
Study: NCT00683449
Drug: Dose Group 2
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusion of MN-221 30 mcg/min for 15 minutes (total dose of 450 mcg)
Study: NCT00683449
Drug: Dose Group 3
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusion of MN-221 16 mcg/min for 15 minutes followed by 8 mcg/min for 105 minutes (total dose = 1,080 mcg)
Study: NCT03133468
Drug: AJM347
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT03133468
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT04643249
Drug: Flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet
Study: NCT03840915
Drug: M7824
Normalized name: M7824
Approvals — FDA: no, EMA: no, PMDA: no
Description: M7824 was administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 and pemetrexed.
Study: NCT04643249
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet or capsule
Study: NCT02433093
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 22 days of once-daily oral matching placebo capsules.
Study: NCT03641976
Drug: Arm II (A-FOLFOX/A-FOLFIRI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm II (A-FOLFOX/A-FOLFIRI)~Biological: bevacizumab Given IV~Drug: fluorouracil Given IV~Drug: irinotecan hydrochloride Given IV~Drug: leucovorin calcium Given IV
Study: NCT00948090
Drug: IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pk-directed IV Busulfan (based on test dose method) for 4 days followed by Etoposide 1400mg/m2 QD for one day and Cyclophosphamide 2.5 g/m2 QD for two days followed by autologous stem cell transplant.
Study: NCT01376427
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate
Study: NCT01819259
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00822211
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02873975
Drug: LY2606368
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02460016
Drug: AK0529
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK0529 pellets for oral administration
Study: NCT02582476
Drug: Bumetanide
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be randomly assigned to either bumetanide or placebo for the first visit. The assigned treatment will be taken by mouth at the onset of a focal attack defined as 40% decrement in ADM CMAP amplitude compared to the maximum CMAP amplitude recorded during or after the exercise. The second assessment will follow an identical protocol to the first, but with the other treatment administered.
Study: NCT00666601
Drug: TR-701 (pro-drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject enrolled in the Main study will receive a single oral dose of 600mg TR-701
Study: NCT02114710
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs
Study: NCT00157560
Drug: Chemotherapy, multiple agents
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02582476
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomly assigned to either bumetanide or placebo for the first visit. The assigned treatment will be taken by mouth at the onset of a focal attack defined as 40% decrement in ADM CMAP amplitude compared to the maximum CMAP amplitude recorded during or after the exercise. The second assessment will follow an identical protocol to the first, but with the other treatment administered.
Study: NCT00244179
Drug: dmard
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00484133
Drug: Dopamine
Normalized name: Dopamine
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03245281
Drug: Diuretic Suspension (DS)
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop diuretic consumption in the 48h before the follow-up visit
Study: NCT00795366
Drug: Standard catecholamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated catecholamine of attending physicians preference to cerebral perfusion pressure greater than 60 mm Hg.
Study: NCT03245281
Drug: Diuretic Increase (DI)
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double diuretics dosage in the 48h before the follow-up visit
Study: NCT03245281
Drug: Diuretic and Medication Suspension (DMS)
Normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop diuretic and MRA medication consumption in the 48h before the follow-up visit
Study: NCT01749956
Drug: FOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00161655
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04603638
Drug: Isotonic
Normalized name: Isotonic solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml
Study: NCT02441231
Drug: Visbiome
Normalized name: Visbiome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visbiome probiotic
Study: NCT03100877
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01689597
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00950586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: To match GSK1034702
Study: NCT03150459
Drug: Simvastatin 20 mg
Normalized name: simvastatin 20 MG
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 20 mg/day for 12 weeks (Group 1)
Study: NCT03150459
Drug: Simvastatin 40mg
Normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40 mg/day for 12 weeks (Group 2)
Study: NCT01911416
Drug: LDE225
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02344316
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taken at 9 PM or 1 hour before bedtime, whichever is earlier
Study: NCT03180177
Drug: adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 3 cycles in control group.
Study: NCT02394769
Drug: Placebo for Aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01120171
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (IV) 600 mg/m2 on day 1. Treatment repeats every 21 days. Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy.~Therapy will continue until maximum response,or unacceptable toxicity.
Study: NCT02856854
Drug: Saline IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine matched placebo
Study: NCT01120171
Drug: Liposomal-encapsulated doxorubicin
Normalized name: liposomal encapsulated paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liposomal-encapsulated doxorubicin (IV) 50 mg/m2 on day 1. Treatment repeats every 21 days.~Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy.~Therapy will continue until maximum response or unacceptable toxicity.
Study: NCT02139761
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
Study: NCT00049140
Drug: EF5
Normalized name: Hb 76(EF5), Met-thr
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02271282
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02271282
Drug: GHRH/Ghrelin combined Injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00468104
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in 100 cc of normal saline was instilled intrapleurally daily for three days
Study: NCT03685604
Drug: PI Disinfection
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PI (Braunoderm® from B.Braun or Betaseptic® from Mundipharma) is applied prior to surgery on the patient's skin with the use of swabs. The product is applied three times. The cumulative residence time is a minimum of 3 minutes. The application is performed according to standard procedures of the participating centers and according to manufacturer's recommendations
Study: NCT00763360
Drug: Healon
Normalized name: Healon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of Healon into the anterior chamber prior to and throughout the cataract surgery procedure
Study: NCT00763360
Drug: Amvisc Plus
Normalized name: Amvisc Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of Amvisc Plus into the anterior chamber prior to and throughout the cataract surgery procedure
Study: NCT03011996
Drug: CLR 500mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: bid for 5 days Cohort 2: bid for 7 days
Study: NCT03011996
Drug: AMX 1g
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cohort 1: bid for 5 days Cohort 2: bid for 7 days
Study: NCT01171365
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo inhaler two inhalations twice daily
Study: NCT01010217
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/kg/day intravenous (IV) over 3 hours on Days 3 and 4.
Study: NCT01840761
Drug: herbal drug
Normalized name: herbal drugs
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01840761
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00962663
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects randomized to receive Ibuprofen will receive placebo to ICA-105665 at all scheduled dosing times on Days 1 to 4 and a single dose of 800 mg Ibuprofen on the morning of Day 4.
Study: NCT00913315
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo once a day for 8 weeks
Study: NCT02615080
Drug: CRD007
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02615080
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00645866
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00962663
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to receive placebo will receive placebo to ICA~-105665 at all scheduled dosing times on Days 1 to 4 and placebo to Ibuprofen on the morning of Day 4.
Study: NCT03062150
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03415087
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intrathecal injection of fentanyl
Study: NCT04207684
Drug: Testosterone injection
Normalized name: testosterone Injection
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 mg of testosterone cypionate (equivalent to 174,8 mg of testosterone) administered via intramuscular injection in a single dose (2 mL)
Study: NCT00305201
Drug: pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03785340
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic buffered saline Eye Drops given 2 times a day for 4 weeks.
Study: NCT02684851
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00003453
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Stage IV Adrenal Gland Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT05409196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine or placebo will be delivered orally as a single dose in Stage 1 and between 2 and 4 doses at 3-day intervals in Stage 2 of the Study.
Study: NCT04717063
Drug: Peroxyl Oral Product
Normalized name: Peroxyl Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: mouth wash
Study: NCT04717063
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo mouth wash